vs
Side-by-side financial comparison of Affinity Bancshares, Inc. (AFBI) and Foghorn Therapeutics Inc. (FHTX). Click either name above to swap in a different company.
Foghorn Therapeutics Inc. is the larger business by last-quarter revenue ($9.2M vs $8.6M, roughly 1.1× Affinity Bancshares, Inc.). Affinity Bancshares, Inc. runs the higher net margin — 24.9% vs -234.3%, a 259.2% gap on every dollar of revenue. On growth, Foghorn Therapeutics Inc. posted the faster year-over-year revenue change (223.8% vs 12.8%). Over the past eight quarters, Foghorn Therapeutics Inc.'s revenue compounded faster (35.3% CAGR vs 8.1%).
Foghorn Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing novel therapies targeting the chromatin regulatory system to treat various types of cancer and other severe diseases. It advances a diverse pipeline of targeted drug candidates, conducting internal R&D and strategic partnerships to serve global patient populations.
AFBI vs FHTX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $8.6M | $9.2M |
| Net Profit | $2.1M | $-21.7M |
| Gross Margin | — | — |
| Operating Margin | 35.9% | -258.2% |
| Net Margin | 24.9% | -234.3% |
| Revenue YoY | 12.8% | 223.8% |
| Net Profit YoY | 58.5% | -11.1% |
| EPS (diluted) | $0.34 | $-0.35 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $8.6M | $9.2M | ||
| Q3 25 | $8.4M | $8.2M | ||
| Q2 25 | $8.3M | $7.6M | ||
| Q1 25 | $7.8M | $6.0M | ||
| Q4 24 | $7.6M | $2.9M | ||
| Q3 24 | $8.0M | $7.8M | ||
| Q2 24 | $8.3M | $6.9M | ||
| Q1 24 | $7.3M | $5.0M |
| Q4 25 | $2.1M | $-21.7M | ||
| Q3 25 | $2.2M | $-15.8M | ||
| Q2 25 | $2.2M | $-17.9M | ||
| Q1 25 | $1.8M | $-18.8M | ||
| Q4 24 | $1.3M | $-19.5M | ||
| Q3 24 | $1.7M | $-19.1M | ||
| Q2 24 | $1.0M | $-23.0M | ||
| Q1 24 | $1.3M | $-25.0M |
| Q4 25 | 35.9% | -258.2% | ||
| Q3 25 | 34.9% | -226.9% | ||
| Q2 25 | 34.1% | -279.2% | ||
| Q1 25 | 30.8% | -385.0% | ||
| Q4 24 | 21.1% | -840.5% | ||
| Q3 24 | 28.5% | -305.5% | ||
| Q2 24 | 16.2% | -386.6% | ||
| Q1 24 | 24.0% | -558.3% |
| Q4 25 | 24.9% | -234.3% | ||
| Q3 25 | 26.5% | -194.4% | ||
| Q2 25 | 25.9% | -237.3% | ||
| Q1 25 | 23.4% | -316.4% | ||
| Q4 24 | 17.7% | -682.9% | ||
| Q3 24 | 21.7% | -244.9% | ||
| Q2 24 | 12.5% | -333.6% | ||
| Q1 24 | 18.2% | -495.4% |
| Q4 25 | $0.34 | $-0.35 | ||
| Q3 25 | $0.34 | $-0.25 | ||
| Q2 25 | $0.33 | $-0.28 | ||
| Q1 25 | $0.28 | $-0.30 | ||
| Q4 24 | $0.21 | $-0.23 | ||
| Q3 24 | $0.26 | $-0.31 | ||
| Q2 24 | $0.16 | $-0.45 | ||
| Q1 24 | $0.20 | $-0.59 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $53.9M | $80.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $127.0M | $-108.5M |
| Total Assets | $881.7M | $198.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $53.9M | $80.9M | ||
| Q3 25 | $84.8M | $89.3M | ||
| Q2 25 | $89.7M | $72.6M | ||
| Q1 25 | $74.7M | $61.0M | ||
| Q4 24 | $41.4M | $55.5M | ||
| Q3 24 | $52.3M | $57.7M | ||
| Q2 24 | $50.4M | $138.9M | ||
| Q1 24 | $61.4M | $79.3M |
| Q4 25 | $127.0M | $-108.5M | ||
| Q3 25 | $125.4M | $-89.7M | ||
| Q2 25 | $124.1M | $-76.7M | ||
| Q1 25 | $122.3M | $-61.7M | ||
| Q4 24 | $129.1M | $-45.5M | ||
| Q3 24 | $128.4M | $-28.3M | ||
| Q2 24 | $125.1M | $-14.3M | ||
| Q1 24 | $123.3M | $-97.5M |
| Q4 25 | $881.7M | $198.1M | ||
| Q3 25 | $925.2M | $205.0M | ||
| Q2 25 | $933.8M | $226.2M | ||
| Q1 25 | $912.5M | $258.7M | ||
| Q4 24 | $866.8M | $284.0M | ||
| Q3 24 | $878.6M | $308.4M | ||
| Q2 24 | $873.6M | $328.6M | ||
| Q1 24 | $869.5M | $255.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $11.6M | $-22.3M |
| Free Cash FlowOCF − Capex | $11.2M | — |
| FCF MarginFCF / Revenue | 130.9% | — |
| Capex IntensityCapex / Revenue | 4.9% | 0.0% |
| Cash ConversionOCF / Net Profit | 5.46× | — |
| TTM Free Cash FlowTrailing 4 quarters | $20.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $11.6M | $-22.3M | ||
| Q3 25 | $3.7M | $-18.9M | ||
| Q2 25 | $3.8M | $-21.0M | ||
| Q1 25 | $1.9M | $-24.0M | ||
| Q4 24 | $6.8M | $-24.5M | ||
| Q3 24 | $4.1M | $-21.0M | ||
| Q2 24 | $619.0K | $-25.5M | ||
| Q1 24 | $1.2M | $-29.3M |
| Q4 25 | $11.2M | — | ||
| Q3 25 | $3.6M | — | ||
| Q2 25 | $3.7M | $-21.0M | ||
| Q1 25 | $1.8M | $-24.0M | ||
| Q4 24 | $6.4M | $-25.0M | ||
| Q3 24 | $4.0M | $-21.3M | ||
| Q2 24 | $489.0K | $-25.6M | ||
| Q1 24 | $1.1M | $-29.4M |
| Q4 25 | 130.9% | — | ||
| Q3 25 | 43.3% | — | ||
| Q2 25 | 44.0% | -278.2% | ||
| Q1 25 | 22.7% | -403.2% | ||
| Q4 24 | 83.9% | -875.3% | ||
| Q3 24 | 49.5% | -273.0% | ||
| Q2 24 | 5.9% | -371.0% | ||
| Q1 24 | 14.8% | -583.1% |
| Q4 25 | 4.9% | 0.0% | ||
| Q3 25 | 0.8% | 0.0% | ||
| Q2 25 | 1.4% | 0.3% | ||
| Q1 25 | 1.9% | 0.5% | ||
| Q4 24 | 5.6% | 16.8% | ||
| Q3 24 | 1.7% | 4.0% | ||
| Q2 24 | 1.6% | 0.2% | ||
| Q1 24 | 1.8% | 2.0% |
| Q4 25 | 5.46× | — | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | 1.75× | — | ||
| Q1 25 | 1.05× | — | ||
| Q4 24 | 5.05× | — | ||
| Q3 24 | 2.36× | — | ||
| Q2 24 | 0.60× | — | ||
| Q1 24 | 0.91× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
